In Europe, 1 man in 3 and 1 woman in 4 will develop cancer before the age of 75. You can reduce and control this risk. So put the odds in your favour!
Primary and secondary prevention
- Nobody is safe from developing cancer. However, you can reduce the risk by 30% by following a few simple rules (primary prevention):
- Don’t smoke
- Maintain a healthy weight
- Eat a balanced diet
- Get regular exercise
- Moderate your alcohol consumption
- Limit your exposure to the sun.
Thanks to screening, certain cancers, including the most common, can be detected at an early stage, even before symptoms appear. Making use of cancer screening is also a way of putting the odds in your favour (secondary prevention).
Our Cancer Prevention and Screening Centre offers a cancer risk assessment service. It is open to all: to those with no particular risk and to those with a known risk. The approach is multidisciplinary: medical, genetic, social, professional and psychological.
Firstly, the Prevention and Screening Centre establishes your risk profile.
We then offer you a personalised prevention plan. This is a customised screening strategy to match your personal situation. We also provide advice, where needed, on lifestyle changes (quitting smoking, diet, exercise, etc). We can help you achieve these goals through our Smoker Support Centre and/or our dieticians.
With your agreement, we will report back to your GP.
The Oncogenetic Clinic, within the Prevention and Screening Clinic at the Jules Bordet Institute and in partnership with the Genetics Centre at the Université Libre de Bruxelles, uses the latest technology to study the impact of the genes involved in the development of hereditary cancers.
Making an appointment
Begin by making an appointment at the Institut Jules Border Cancer Prevention and Screening Centre:
- By phone: +32 (0)2 541 30 50
- By fax: +32 (0)2 541 31 76
- By online forms
Once your appointment has been confirmed, you will receive a questionnaire on your state of health and your lifestyle. You can complete this in complete confidence. It will serve as the basis for your discussion with the doctor when you have your appointment.
Consultation with the doctor
On the day of your appointment, bring your completed questionnaire with you. There is no need to have fasted. Our prevention and screening centre is located on the ground floor of 90, Rue Meylemeersch - 1070 Anderlecht. Follow the road 2080. It is advisable to arrive 15 minutes beforehand.
You will be seen by a general practitioner specialising in prevention and screening. During your consultation, your risk level will be assessed on the basis of the evaluation questionnaire. Your age, gender, personal and family history, your lifestyle and professional profile will all be taken into account. A full clinical examination will also be carried out.
Depending on your risk profile, the doctor may offer additional examinations such as medical imaging, blood analysis, etc.
Depending on your risk profile, specialist consultations may also be offered.
- Dermatology consultation: to check any skin anomalies (recent change in the size or colour of a mole, for example).
- Nutritional consultation: to correct an unbalanced diet and/or excess weight by dieting and/or dietary advice.
- Consultation with the Institut Jules Bordet Smoker Support Centre: we take a medical, pharmacological, psychological and behavioural approach. There are three phases in quitting smoking: preparatory phase, detox phase and consolidation phase.
- Screening test for osteoporosis: to check your bone capital after the menopause.
- Dr Jean-Benoît BURRION, Clinical Director
- Dr Françoise ANCIAUX
- Dr Thierry CARBONEZ
- Dr Claire LEFERE
- Dr Anne-Marie SCHRAUWEN
- Dr Evelyne STAQUET
- Dr Danièle TAES
- Dr Elie CHAMOUN, Dermatology
- Dr Daphné T’KINT de ROODENBEKE, Oncogenetic advice
- Mrs Martine DELMELLE, Oncogenetic advice
- Martial BODO, Tabacologie
- Hilde VANDECASTEELE, Tabacologie
- Mrs Laurence GILSON, Tabacologie
MyPEBS: European project comparing the strategy of the breast cancer screening programme ("Mammotest") with a screening strategy that takes into account the individual risk factor. This eight-year project financed by the European Commission (Horizon 2020) started up in 2019. For more information, or if you would like to participate in this study, go to https://www.mypebs.eu/
Implementation of fetal clinical exome sequencing: Comparing prospective and retrospective cohorts.
Authors : Marangoni M, Smits G, Ceysens G, Costa E, Coulon R, Daelemans C, De Coninck C, Derisbourg S, Gajewska K, Garofalo G, Gounongbe C, Guizani M, Holoye A, Houba C, Makhoul J, Norgaard C, Regnard C, Romée S, Soto J, Stagel-Trabbia A, Van Rysselberge M, Vercoutere A, Zaytouni S, Bouri S, DHaene N, DOnle D, Dugauquier C, Racu ML, Rocq L, Segers V, Verocq C, Avni EF, Cassart M, Massez A, Blaumeiser B, Brischoux-Boucher E, Bulk S, De Ravel T, Debray G, Dimitrov B, Janssens S, Keymolen K, Laterre M, van Berkel K, Van Maldergem L, Vandernoot I, Vilain C, Donner C, Tecco L, Thomas D, Désir J, Abramowicz M, Migeotte I
Year : 2022
Journal : Genet Med
Volume : 24
Pages : 344-363
Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the My Personal Breast Screening" (MyPeBS) randomised clinical trial."
Authors : Roux A, Cholerton R, Sicsic J, Moumjid N, French DP, Giorgi Rossi P, Balleyguier C, Guindy M, Gilbert FJ, Burrion JB, Castells X, Ritchie D, Keatley D, Baron C, Delaloge S, de Montgolfier S
Year : 2022
Journal : BMC Cancer
Volume : 22
Pages : 507
Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease.
Authors : Spilleboudt C, de Wilde V, Lewalle P, Cabanne L, Leclerc M, Beckerich F, Bories D, Cardoso S, Soares MP, Vokaer B, Hougardy JM, Flamand V, Racapé J, Abramowicz M, Maury S, Le Moine A
Year : 2021
Journal : Front Immunol
Volume : 11
Pages : 579151
Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks.
Authors : Kehrloesser S, Oberst S, Westerhuis W, Wendler A, Wind A, Blaauwgeers H, Burrion JB, Nagy P, Saeter G, Gustafsson E, De Paoli P, Lovey J, Lombardo C, Philip T, de Valeriola D, Docter M, Boomsma F, Saghatchian M, Svoboda M, Philip I, Monetti F, Hummel H, McVie G, Otter R, Van Harten W
Year : 2021
Journal : Mol Oncol
Volume : 15
Pages : 1277-1288
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Authors : Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, Tkint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ
Year : 2021
Journal : Prostate Cancer Prostatic Dis